COVID-19, COVID-19 Drug Treatment, Severe Acute Respiratory Syndrome Coronavirus 2
Conditions
Keywords
COVID-19, Combination therapy, Atorvastatin, Telmisartan, Lopinavir/ritonavir, SARS-COV-2, Viral load
Brief summary
In January 2020, the new SARS-CoV-2 coronavirus was identified in China. The disease caused by this coronavirus was named COVID-19 by the World Health Organization (WHO). Since March 11, 2020, the WHO has described the global situation of COVID-19 as a pandemic. In Côte d'Ivoire, as in other African countries, the number of cases is increasing exponentially. Coronaviruses are a family of viruses that cause illnesses ranging from the common cold to more severe pathologies. COVID-19 can result in fever or a feeling of fever (chills, hot-cold), cough, headache, aches and pains, unusual tiredness, sudden loss of smell, total disappearance of taste, or diarrhea. In severe forms, respiratory difficulties can lead to hospitalization in intensive care or even death. Numerous studies are currently being conducted around the world to seek effective treatment, but few of them have started specifically in Africa. Moreover, most of these studies are using a single drug to control the infection, whether these are repositioned drugs, i.e. already being used for other diseases, or other newer drugs. Currently in Côte d'Ivoire, the preferred treatment for COVID-19 is an antiviral: lopinavir/ritonavir (LPV/r), usually directed against the Human Immunodeficiency Virus (HIV). Since the number of viruses (viral load) is high in the respiratory tract during COVID-19 infection, we propose in INTENSE-COV (ICOV) clinical trial to study whether the combination of two drugs is more effective than taking a single drug on reducing the viral load in the respiratory tract but also on reducing inflammation. These drugs include the LPV/r already in use in Côte d'Ivoire as well as an antihypertensive drug - telmisartan, and a drug that lowers blood cholesterol - atorvastatin. All three have been known for a long time and have been shown to be effective against other viruses. In addition, they are generic, inexpensive and readily available in all countries. The objectives of the ICOV study are therefore to improve viral eradication from the patient's body and respiratory tract, to reduce inflammation, to improve more rapidly the patient's state of health and to reduce the risk of transmission of the virus to others. To participate in ICOV, patients must be over 18 years of age, have a COVID-19 infection confirmed by a specific test, have clinical manifestations of the infection, and have signed an informed consent. They will then be randomized into 3 treatment groups to ensure the robustness of the study results. The reference group will be treated with LPV/r, according to current recommendations in Côte d'Ivoire. The other 2 groups will be treated with LPV/r + telmisartan and LPV/r + atorvastatin respectively. The treatment will last 10 days and patients will be followed for a total of 28 days.
Interventions
DRUGLopinavir/Ritonavir 200 MG-50 MG Oral Tablet
2 tablets morning and evening from Day 1 to Day 10
DRUGTelmisartan 40Mg Oral Tablet
1 tablet daily from Day 1 to Day 10
1 tablet daily from Day 1 to Day 10
Sponsors
University of Bordeaux
PACCI Program
ANRS, Emerging Infectious Diseases
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Phase IIb, comparative, multicenter, randomized, superiority, parallel-group, open-label clinical trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients over 18 years of age. * With SARS-CoV-2 infection confirmed by specific PCR. * With clinical manifestations of the infection, such as fever or cough, or otolaryngologic (ORL) signs or respiratory difficulties, that started less than 7 days ago. * COVID-19 specific treatment-naive. * Women of childbearing age should accept the use of mechanical contraception during the study period. * Informed consent signed by the patient.
Exclusion criteria
* Severe form of infection requiring oxygen therapy \> 4l/min to achieve oxygen saturation \> 94%. * Patient whose weight is \< 35kg. * Pharmacological investigation contraindicating the introduction of a CYP450 inhibitor, in particular the CYP3A4 isoform. * Known hypersensitivity to lopinavir, ritonavir, telmisartan, atorvastatin or their excipients. * Renal impairment (eGFR \<30 mL/min, CKD-EPI formulation). * Known cirrhosis. * Transaminases \> 3N. * Bilirubin \> 2.6N. * Electrocardiogram showing QTc\> 500 ms. * HIV-infected patient without treatment or treated with protease inhibitors (lopinavir, darunavir, atazanavir). * Ongoing exposure to statins. * Contraindications to the use of statin: CPK \> 5N, history of rhabdomyolysis or myopathies, increased risk when atorvastatin is administered with strong CYP3A4 inhibitors or transport proteins (cyclosporin, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole, letermovir, erythromycin, diltiazem, verapamil, fluconazole). * Ongoing exposure to sartans. * Contraindications to the use of telmisartan: patient on angiotensin-converting enzyme (ACE) inhibitors, aliskiren or other angiotensin receptor blockers (ARB). * Curatorship or guardianship. * Pregnancy or breastfeeding. * Dementia or any other condition that prevents informed consent. * Any reason that, at the discretion of the investigator, would compromise patient safety and cooperation in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with undetectable nasopharyngeal swab SARS-CoV-2 PCR and C-reactive protein (CRP) < 27 mg/L at Day 11 | Day 11 |
Secondary
| Measure | Time frame |
|---|---|
| Kinetics of SARS-CoV-2 viral load | Up to Day 28 |
| Death rate at Day 11 and Day 28 | Day 11 and Day 28 |
| All causes of death and Acute respiratory distress syndrome (ARDS) at Day 28 | Day 28 |
| Time to hospital discharge | Up to Day 28 |
| Duration of oxygen supplementation | Up to Day 28 |
| Proportion of patients with clinical improvement on the 7-point ordinal scale at Day 11 and Day 28 | Day 11 and Day 28 |
| Residual concentration of lopinavir, telmisartan and atorvastatin | Up to Day 28 |
| Evolution of inflammatory and immunological markers (CRP, fibrinogen, ferritin, d-dimer, dosing of IgG, IgA, IgM; TCD4, CD8, B lymphocytes, NK lymphocytes; naïve/memory T lymphocytes) | Up to Day 28 |
| Evolution of endothelial activation markers (VEGF and soluble VEGF receptor,VE-cadherin, PECAM/CD31, CD42 and angiopoietin-2) | Up to Day 28 |
| Proportion of patients with good results according to HIV status | Up to Day 28 |
| Number of contact cases infected by COVID-19 at Day 28 | Day 28 |
| Prevalence of grade III or IV adverse events | Up to Day 28 |
Countries
Côte d’Ivoire
Outcome results
None listed